Medpace Holdings, Inc.

  • Health Care
  • Biotechnology: Commercial Physical & Biological Resarch
  • www.medpace.com
  • Earnings Score
  • Moat Score
  • Market Cap $8.62B
  • PE 21
  • Debt -
  • Cash $441.44M
  • EV -
  • FCF $540.93M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$416.39M
EBIT$481.31M
ROE70%
ROA25%
FCF$540.93M
Equity$593.61M
Growth Stability100%
PE20.71
PEG0.71
PB14.53
P/FCF15.94
P/S4
Price/Cash0.05
Net Margins21%
Op. Margins22%
Earnings CAGR48%
Sales Growth YoY9%
Sales Growth QoQ4%
Sales CAGR23%
FCF CAGR27%
Equity CAGR0%
Earnings Stability0.89
Earnings Growth YoY12%
Earnings Growth QoQ-2%
Earnings CAGR 5Y29%
Sales CAGR 5Y24%
FCF CAGR 5Y27%
Equity CAGR 5Y-5%
Earnings CAGR 3Y21%
Sales CAGR 3Y21%
FCF CAGR 3Y32%
Equity CAGR 3Y47%
Market Cap$8.62B
Revenue$2.16B
Assets$1.90B
Cash$441.44M
Shares Outstanding29.84M
Earnings Score95%
Moat Score97%
Working Capital-300.87M
Current Ratio0.73
Shares Growth 3y-1%
Equity Growth QoQ-28%
Equity Growth YoY-12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin America.

SEC Filings

Direct access to Medpace Holdings, Inc. (MEDP) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Medpace Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Medpace Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 48%
Stability 89%
loading chart...

Medpace Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Medpace Holdings, Inc..

= $36B
012345678910TV
fcf$541M$688M$874M$1.1B$1.4B$1.8B$2.3B$2.9B$3.7B$4.7B$6B$60B
DCF$625M$722M$835M$964M$1.1B$1.3B$1.5B$1.7B$2B$2.3B$23B
Value$36B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-2%3%9%10%12%16%16%17%15%19%21%
ROA-5%7%10%11%12%12%21%20%23%25%
ROE-2%8%12%14%18%19%63%51%49%70%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-2.272.790.570-00.140--
Debt over Equity0.940.290.470.140-00.130--
Growth Stability---100%100%100%100%100%100%100%100%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-17%3%62%22%8%23%28%29%12%24%
Earnings YoY growth--254%191%87%37%45%25%35%15%43%29%
Equity YoY growth-48%-18%17%23%11%18%-59%45%48%-5%
FCF YoY growth--2%10%64%31%24%3%49%13%44%27%